The collaboration will focus on the development of a portfolio of AGTC’s therapeutic programs, including both a clinical stage candidate and a pre-clinical candidate for orphan diseases of
KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed
Rociletinib is the Company’s novel, oral targeted covalent (irreversible) mutant-selective inhibitor of EGFR in development for the treatment of NSCLC in patients with initial activating EGFR mutations, as
Alchemia Oncology Pty Limited has a robust collection of clinical and pre-clinical oncology assets, which include the HyACT Drug Delivery Platform, a portfolio of targeted therapeutics which are
New companies Lupin and Strides Arcolab recently signed agreements to produce dolutegravir (DTG), a promising new HIV medicine the MPP licensed from ViiV Healthcare two months after its
The fact that R-Japan received the license of cell processing facility through the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, 2015 two months after
Breckenridge and Alembic filed their Paragraph IV ANDA on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers. Alembic Pharmaceuticals Limited is the
Pickwick will focus on assisting Nutra Pharma in its strategies for maximizing shareholder value through its full scope of investment banking services. "Nutra Pharma is in the process
Stuart W. Titus, PhD, President and CEO of Medical Marijuana Inc. mentions: "We are extremely excited to announce our strategic ownership interest in AXIM Biotech and explain to
With the close of this acquisition, management believes that the Company will be able to offer comprehensive immuno-oncology cell therapy portfolios, as well as a broad set of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.